Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?

[1]  S. Son,et al.  Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer. , 2015, Gynecologic oncology.

[2]  T. Ichikawa,et al.  Whole-body total lesion glycolysis measured on fluorodeoxyglucose positron emission tomography/computed tomography as a prognostic variable in metastatic breast cancer , 2014, BMC Cancer.

[3]  Hiroshi Honda,et al.  Diagnostic and Prognostic Value of Pretreatment SUV in 18F-FDG/PET in Breast Cancer: Comparison with Apparent Diffusion Coefficient from Diffusion-Weighted MR Imaging , 2014, The Journal of Nuclear Medicine.

[4]  B. Ljung,et al.  Breast cancer version 3.2014. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[5]  M. Raica,et al.  Hormone receptors and HER2 expression in primary breast carcinoma and corresponding lymph node metastasis: do we need both? , 2014, Anticancer research.

[6]  Hiroshi Onishi,et al.  Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value. , 2013, Radiology.

[7]  E. Ozkan.  Positron emission tomography/computed tomography in locally advanced breast cancer. , 2013, Experimental oncology.

[8]  B. Yalcin.  Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy. , 2013, Experimental oncology.

[9]  M. Okada,et al.  Role of maximum standardized uptake value in fluorodeoxyglucose positron emission tomography/computed tomography predicts malignancy grade and prognosis of operable breast cancer: a multi-institute study , 2013, Breast Cancer Research and Treatment.

[10]  C. Perou,et al.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013 , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  M. Hatt,et al.  Estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast tumors , 2013, Cancer.

[12]  S. Son,et al.  Prognostic value of whole-body metabolic tumour volume and total lesion glycolysis measured on 18F-FDG PET/CT in patients with extranodal NK/T-cell lymphoma , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  Yongxue Zhang,et al.  Prognostic Predictive Value of Total Lesion Glycolysis From 18F-FDG PET/CT in Post-Surgical Patients With Epithelial Ovarian Cancer , 2013, Clinical nuclear medicine.

[14]  J. Ragaz,et al.  The SUVmax for 18F-FDG Correlates With Molecular Subtype and Survival of Previously Untreated Metastatic Breast Cancer , 2013, Clinical nuclear medicine.

[15]  J. Min,et al.  Prognostic Significance of Metabolic Tumor Volume Measured by 18F-FDG PET/CT in Operable Primary Breast Cancer , 2012, Nuclear Medicine and Molecular Imaging.

[16]  Nan-Tsing Chiu,et al.  Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. , 2012, Radiology.

[17]  Kyoungjune Pak,et al.  Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer , 2012, Nuclear medicine communications.

[18]  J. Min,et al.  Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  D. Groheux,et al.  The Yield of 18F-FDG PET/CT in Patients with Clinical Stage IIA, IIB, or IIIA Breast Cancer: A Prospective Study , 2011, The Journal of Nuclear Medicine.

[20]  Kyoungjune Pak,et al.  The Prognostic Value of the Metabolic Tumor Volume in FIGO stage IA to IIB Cervical Cancer for Tumor Recurrence: Measured by F-18 FDG PET/CT , 2011, Nuclear medicine and molecular imaging.

[21]  C. Reddy,et al.  Maximum standardized uptake value from staging FDG-PET/CT does not predict treatment outcome for early-stage non-small-cell lung cancer treated with stereotactic body radiotherapy. , 2010, International journal of radiation oncology, biology, physics.

[22]  Kyung Soo Lee,et al.  Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications , 2010, Annals of Surgical Oncology.

[23]  Brit B. Turnbull,et al.  Metabolic tumor volume predicts for recurrence and death in head-and-neck cancer. , 2008, International journal of radiation oncology, biology, physics.

[24]  Su Jin Lee,et al.  Prognostic Value of Metabolic Tumor Volume Measured by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients with Esophageal Carcinoma , 2009, Annals of Surgical Oncology.

[25]  Z. Baloch,et al.  Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. , 1995, Journal of the American College of Surgeons.